1. Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M, et al. Postzygotic
HRAS and
KRAS mutations cause nevus sebaceus and Schimmelpenning syndrome. Nat Genet. 2012; 44:783–787. PMID:
22683711.
2. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441:424–430. PMID:
16724053.
Article
3. Aslam A, Salam A, Griffiths CE, McGrath JA. Naevus sebaceus: a mosaic RASopathy. Clin Exp Dermatol. 2014; 39:1–6. PMID:
24341474.
Article
4. Levinsohn JL, Tian LC, Boyden LM, McNiff JM, Narayan D, Loring ES, et al. Whole-exome sequencing reveals somatic mutations in
HRAS and
KRAS, which cause nevus sebaceus. J Invest Dermatol. 2013; 133:827–830. PMID:
23096712.
5. Happle R. Nevus sebaceus is a mosaic RASopathy. J Invest Dermatol. 2013; 133:597–600. PMID:
23399824.
Article
6. Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, et al. Germline
KRAS mutations cause Noonan syndrome. Nat Genet. 2006; 38:331–336. PMID:
16474405.
7. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, et al. Germline mutations in
HRAS proto-oncogene cause Costello syndrome. Nat Genet. 2005; 37:1038–1040. PMID:
16170316.
8. Brandling-Bennett HA, Morel KD. Epidermal nevi. Pediatr Clin North Am. 2010; 57:1177–1198. PMID:
20888465.
Article
9. Sun BK, Saggini A, Sarin KY, Kim J, Benjamin L, LeBoit PE, et al. Mosaic activating
RAS mutations in nevus sebaceus and nevus sebaceus syndrome. J Invest Dermatol. 2013; 133:824–827. PMID:
23096709.